ArticleAntimicrobial agents and chemotherapy2002
Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 73 citations in OpenAlex.
- Identification of genes and mutations involved in antimicrobial low susceptibility inMicrobiology spectrum · 2026Article
- Article
- Evolution and characteristics of tetracycline resistance inMicrobiology spectrum · 2025Article
- Unravelling Antimicrobial Resistance inVeterinary sciences · 2024Review
- Evaluation of commercial, customized microdilution plates forJournal of clinical microbiology · 2024Article
- Drug Susceptibility Test and Analysis of Quinolone Resistance Genes inInfection and drug resistance · 2023Article
- Phenotypic and genetic insights into efflux pump mechanism inFrontiers in microbiology · 2023Article
- The effects of magainin 2-derived and rationally designed antimicrobial peptides on Mycoplasma pneumoniae.PloS one · 2022Article
- Emergence and Mechanism of Resistance of Tulathromycin AgainstFrontiers in veterinary science · 2022Article
- Resistance to 16-Membered Macrolides, Tiamulin and Lincomycin in a Swine Isolate ofAntibiotics (Basel, Switzerland) · 2021Article
- Genome-Wide Association Study Reveals Genetic Markers for Antimicrobial Resistance in Mycoplasma bovis.Microbiology spectrum · 2021Article
- Integrating the Human and Animal Sides of Mycoplasmas Resistance to Antimicrobials.Antibiotics (Basel, Switzerland) · 2021Review
- Efflux Might Participate in Decreased Susceptibility to Oxytetracycline in Contagious Agalactia-CausativeAnimals : an open access journal from MDPI · 2021Article
- Quantitative proteomics analysis of Mycoplasma pneumoniae identifies potential macrolide resistance determinants.AMB Express · 2021Article
- A GC-Rich Prophage-Like Genomic Region of Mycoplasma bovirhinis HAZ141_2 Carries a Gene Cluster Encoding Resistance to Kanamycin and Neomycin.Antimicrobial agents and chemotherapy · 2021Article
- Determination of Drug Efflux Pump Efficiency in Drug-Resistant Bacteria Using MALDI-TOF MS.Antibiotics (Basel, Switzerland) · 2020Article
- Identification of a Novel Polyamine Scaffold With Potent Efflux Pump Inhibition Activity Toward Multi-Drug Resistant Bacterial Pathogens.Frontiers in microbiology · 2018Article
- Mycoplasma genitalium: whole genome sequence analysis, recombination and population structure.BMC genomics · 2017Article
- Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal.Applied and environmental microbiology · 2016Article
- Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.Frontiers in microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The uptake of fluoroquinolones was characterized for the fluoroquinolone-susceptible strain PG21 of Mycoplasma hominis. Accumulation of fluoroquinolones appeared to occur by passive diffusion. Addition of arginine as the energizer significantly reduced the uptake of fluoroquinolones, suggesting the presence of an energy-dependent efflux process. Reserpine and orthovanadate, two multidrug pump inhibitors, increased significantly the ciprofloxacin (CIP) uptake. In contrast, such a strong effect was not observed for moxifloxacin and pefloxacin uptakes. Two ethidium bromide (EtBr)-resistant strains, selected in vitro, showed a resistance profile compatible with a multidrug-resistant phenotype, with increased MICs for the hydrophilic fluoroquinolones, CIP and norfloxacin, EtBr, and acriflavine. Taking the EtBr-resistant strain RB1La as a model, a significant decrease of the CIP and EtBr uptakes was observed compared to the reference strain PG21. In the presence of reserpine and orthovanadate, both inhibitors of ATP-dependent efflux pumps, the CIP uptake increased significantly, reaching approximately the same level as that of the susceptible strain. Similar results were obtained with EtBr uptake and efflux experiments. Our data suggest the presence of an active efflux system, possibly an ABC-type efflux pump, implicated in the resistance to CIP and unrelated compounds like EtBr in the human mycoplasma M. hominis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.